Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Amgen to present Enbrel trial data

Amgen to present Enbrel trial data

19th October 2009

Amgen will present data from clinical trials into its rheumatoid arthritis treatment Enbrel (etanercept) at an arthritis meeting this week, it has revealed.

The data are part of 17 years of trials conducted around the drug, which has an established safety profile.

Enbrel, a soluble form of a fully human tumor necrosis factor, was first approved in 1998 for moderate to severe rheumatoid arthritis and was later authorised to treat children and adolescents with juvenile rheumatoid arthritis in 1999.

It was approved again in 2004 to treat moderate to severe plaque psoriasis in adults.

Sean Harper, senior vice-president and chief medical officer at Amgen, said: “New data from an established therapy such as Enbrel continues to inform the medical and scientific community with the goal of advancing patient care.”

Last month, Amgen said that it was “very pleased” with the outcome of a trial which found that its first-line metastatic colorectal cancer drug Vectibix administered in combination with Folfox noticeably improves the survival period of patients.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.